A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

12/29/2022, 4:33 PM

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Congress
117
Number
S - 4152
Introduced on
2022-05-05
# Amendments
0
Sponsors
+5
Cosponsors
+5

Variations and Revisions

5/5/2022
Text
PDF
XML

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Alternative Names
Official Title as IntroducedA bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
Policy Areas
Health

Comments

Related

Bill Update Alert:  FDASLA Act of 2022

Recent Activity

Latest Summary10/18/2022

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Latest Action5/5/2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.